Cargando…
COVID-19 in patients with lung cancer
BACKGROUND: Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific features that impact the severity of COVID-19 may inform optimal cancer care during this pandemic. PATIENTS AND METHODS: We e...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297689/ https://www.ncbi.nlm.nih.gov/pubmed/32561401 http://dx.doi.org/10.1016/j.annonc.2020.06.007 |
_version_ | 1783547057462575104 |
---|---|
author | Luo, J. Rizvi, H. Preeshagul, I.R. Egger, J.V. Hoyos, D. Bandlamudi, C. McCarthy, C.G. Falcon, C.J. Schoenfeld, A.J. Arbour, K.C. Chaft, J.E. Daly, R.M. Drilon, A. Eng, J. Iqbal, A. Lai, W.V. Li, B.T. Lito, P. Namakydoust, A. Ng, K. Offin, M. Paik, P.K. Riely, G.J. Rudin, C.M. Yu, H.A. Zauderer, M.G. Donoghue, M.T.A. Łuksza, M. Greenbaum, B.D. Kris, M.G. Hellmann, M.D. |
author_facet | Luo, J. Rizvi, H. Preeshagul, I.R. Egger, J.V. Hoyos, D. Bandlamudi, C. McCarthy, C.G. Falcon, C.J. Schoenfeld, A.J. Arbour, K.C. Chaft, J.E. Daly, R.M. Drilon, A. Eng, J. Iqbal, A. Lai, W.V. Li, B.T. Lito, P. Namakydoust, A. Ng, K. Offin, M. Paik, P.K. Riely, G.J. Rudin, C.M. Yu, H.A. Zauderer, M.G. Donoghue, M.T.A. Łuksza, M. Greenbaum, B.D. Kris, M.G. Hellmann, M.D. |
author_sort | Luo, J. |
collection | PubMed |
description | BACKGROUND: Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific features that impact the severity of COVID-19 may inform optimal cancer care during this pandemic. PATIENTS AND METHODS: We examined consecutive patients with lung cancer and confirmed diagnosis of COVID-19 (n = 102) at a single center from 12 March 2020 to 6 May 2020. Thresholds of severity were defined a priori as hospitalization, intensive care unit/intubation/do not intubate ([ICU/intubation/DNI] a composite metric of severe disease), or death. Recovery was defined as >14 days from COVID-19 test and >3 days since symptom resolution. Human leukocyte antigen (HLA) alleles were inferred from MSK-IMPACT (n = 46) and compared with controls with lung cancer and no known non-COVID-19 (n = 5166). RESULTS: COVID-19 was severe in patients with lung cancer (62% hospitalized, 25% died). Although severe, COVID-19 accounted for a minority of overall lung cancer deaths during the pandemic (11% overall). Determinants of COVID-19 severity were largely patient-specific features, including smoking status and chronic obstructive pulmonary disease [odds ratio for severe COVID-19 2.9, 95% confidence interval 1.07–9.44 comparing the median (23.5 pack-years) to never-smoker and 3.87, 95% confidence interval 1.35–9.68, respectively]. Cancer-specific features, including prior thoracic surgery/radiation and recent systemic therapies did not impact severity. Human leukocyte antigen supertypes were generally similar in mild or severe cases of COVID-19 compared with non-COVID-19 controls. Most patients recovered from COVID-19, including 25% patients initially requiring intubation. Among hospitalized patients, hydroxychloroquine did not improve COVID-19 outcomes. CONCLUSION: COVID-19 is associated with high burden of severity in patients with lung cancer. Patient-specific features, rather than cancer-specific features or treatments, are the greatest determinants of severity. |
format | Online Article Text |
id | pubmed-7297689 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72976892020-06-17 COVID-19 in patients with lung cancer Luo, J. Rizvi, H. Preeshagul, I.R. Egger, J.V. Hoyos, D. Bandlamudi, C. McCarthy, C.G. Falcon, C.J. Schoenfeld, A.J. Arbour, K.C. Chaft, J.E. Daly, R.M. Drilon, A. Eng, J. Iqbal, A. Lai, W.V. Li, B.T. Lito, P. Namakydoust, A. Ng, K. Offin, M. Paik, P.K. Riely, G.J. Rudin, C.M. Yu, H.A. Zauderer, M.G. Donoghue, M.T.A. Łuksza, M. Greenbaum, B.D. Kris, M.G. Hellmann, M.D. Ann Oncol Original Article BACKGROUND: Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific features that impact the severity of COVID-19 may inform optimal cancer care during this pandemic. PATIENTS AND METHODS: We examined consecutive patients with lung cancer and confirmed diagnosis of COVID-19 (n = 102) at a single center from 12 March 2020 to 6 May 2020. Thresholds of severity were defined a priori as hospitalization, intensive care unit/intubation/do not intubate ([ICU/intubation/DNI] a composite metric of severe disease), or death. Recovery was defined as >14 days from COVID-19 test and >3 days since symptom resolution. Human leukocyte antigen (HLA) alleles were inferred from MSK-IMPACT (n = 46) and compared with controls with lung cancer and no known non-COVID-19 (n = 5166). RESULTS: COVID-19 was severe in patients with lung cancer (62% hospitalized, 25% died). Although severe, COVID-19 accounted for a minority of overall lung cancer deaths during the pandemic (11% overall). Determinants of COVID-19 severity were largely patient-specific features, including smoking status and chronic obstructive pulmonary disease [odds ratio for severe COVID-19 2.9, 95% confidence interval 1.07–9.44 comparing the median (23.5 pack-years) to never-smoker and 3.87, 95% confidence interval 1.35–9.68, respectively]. Cancer-specific features, including prior thoracic surgery/radiation and recent systemic therapies did not impact severity. Human leukocyte antigen supertypes were generally similar in mild or severe cases of COVID-19 compared with non-COVID-19 controls. Most patients recovered from COVID-19, including 25% patients initially requiring intubation. Among hospitalized patients, hydroxychloroquine did not improve COVID-19 outcomes. CONCLUSION: COVID-19 is associated with high burden of severity in patients with lung cancer. Patient-specific features, rather than cancer-specific features or treatments, are the greatest determinants of severity. European Society for Medical Oncology. Published by Elsevier Ltd. 2020-10 2020-06-17 /pmc/articles/PMC7297689/ /pubmed/32561401 http://dx.doi.org/10.1016/j.annonc.2020.06.007 Text en © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Luo, J. Rizvi, H. Preeshagul, I.R. Egger, J.V. Hoyos, D. Bandlamudi, C. McCarthy, C.G. Falcon, C.J. Schoenfeld, A.J. Arbour, K.C. Chaft, J.E. Daly, R.M. Drilon, A. Eng, J. Iqbal, A. Lai, W.V. Li, B.T. Lito, P. Namakydoust, A. Ng, K. Offin, M. Paik, P.K. Riely, G.J. Rudin, C.M. Yu, H.A. Zauderer, M.G. Donoghue, M.T.A. Łuksza, M. Greenbaum, B.D. Kris, M.G. Hellmann, M.D. COVID-19 in patients with lung cancer |
title | COVID-19 in patients with lung cancer |
title_full | COVID-19 in patients with lung cancer |
title_fullStr | COVID-19 in patients with lung cancer |
title_full_unstemmed | COVID-19 in patients with lung cancer |
title_short | COVID-19 in patients with lung cancer |
title_sort | covid-19 in patients with lung cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297689/ https://www.ncbi.nlm.nih.gov/pubmed/32561401 http://dx.doi.org/10.1016/j.annonc.2020.06.007 |
work_keys_str_mv | AT luoj covid19inpatientswithlungcancer AT rizvih covid19inpatientswithlungcancer AT preeshagulir covid19inpatientswithlungcancer AT eggerjv covid19inpatientswithlungcancer AT hoyosd covid19inpatientswithlungcancer AT bandlamudic covid19inpatientswithlungcancer AT mccarthycg covid19inpatientswithlungcancer AT falconcj covid19inpatientswithlungcancer AT schoenfeldaj covid19inpatientswithlungcancer AT arbourkc covid19inpatientswithlungcancer AT chaftje covid19inpatientswithlungcancer AT dalyrm covid19inpatientswithlungcancer AT drilona covid19inpatientswithlungcancer AT engj covid19inpatientswithlungcancer AT iqbala covid19inpatientswithlungcancer AT laiwv covid19inpatientswithlungcancer AT libt covid19inpatientswithlungcancer AT litop covid19inpatientswithlungcancer AT namakydousta covid19inpatientswithlungcancer AT ngk covid19inpatientswithlungcancer AT offinm covid19inpatientswithlungcancer AT paikpk covid19inpatientswithlungcancer AT rielygj covid19inpatientswithlungcancer AT rudincm covid19inpatientswithlungcancer AT yuha covid19inpatientswithlungcancer AT zauderermg covid19inpatientswithlungcancer AT donoghuemta covid19inpatientswithlungcancer AT łukszam covid19inpatientswithlungcancer AT greenbaumbd covid19inpatientswithlungcancer AT krismg covid19inpatientswithlungcancer AT hellmannmd covid19inpatientswithlungcancer |